Andres Elia

Consejo Nacional De Investigaciones Científicas Y Técnicas, B, Argentina

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Nuclear FGF2, androgen receptor and Wnt pathway activation define a targetable subset of antiprogestin-resistant luminal breast cancer.

Nuclear FGF2, androgen receptor and Wnt pathway activation define a targetable subset of antiprogestin-resistant luminal breast cancer.

Journal: British journal of cancer

Published: October 03, 2025

Steroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American country.

Steroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American country.

Journal: Scientific reports

Published: September 10, 2024

Antiprogestins for breast cancer treatment: We are almost ready.

Antiprogestins for breast cancer treatment: We are almost ready.

Journal: The Journal of steroid biochemistry and molecular biology

Published: November 29, 2023

Tumor Lipid Signatures Are Descriptive of Acquisition of Therapy Resistance in an Endocrine-Related Breast Cancer Mouse Model.

Tumor Lipid Signatures Are Descriptive of Acquisition of Therapy Resistance in an Endocrine-Related Breast Cancer Mouse Model.

Journal: Journal of proteome research

Published: July 27, 2023

Steroid profile in patients with breast cancer and in mice treated with mifepristone.

Steroid profile in patients with breast cancer and in mice treated with mifepristone.

Journal: Endocrine-related cancer

Published: July 25, 2023

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models.

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models.

Journal: Scientific reports

Published: November 13, 2022

Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial.

Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 30, 2022

Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1.

Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1.

Journal: International journal of cancer

Published: September 03, 2021

Increased androgen receptor expression in estrogen receptor-positive/progesterone receptor-negative breast cancer.

Increased androgen receptor expression in estrogen receptor-positive/progesterone receptor-negative breast cancer.

Journal: Breast cancer research and treatment

Published: December 09, 2019

Increased High Molecular Weight FGF2 in Endocrine-Resistant Breast Cancer.

Increased High Molecular Weight FGF2 in Endocrine-Resistant Breast Cancer.

Journal: Hormones & cancer

Published: March 14, 2018

Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness.

Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness.

Journal: Journal of the National Cancer Institute

Published: July 27, 2016

Showing 1-11 of 11

Last Updated: 09/26/2026